Visual Abstract

Introduction: No head-to-head trials compare iGlarLixi, a fixed-ratio combination of basal insulin (BI) and glucagon-like peptide-1 receptor agonist, with IDegAsp, a co-formulation of BI analog and meal-time insulin.

Methods: A systematic literature search of randomized controlled trials (RCTs) of iGlarLixi and IDegAsp vs. comparators was carried out. Studies were compared by an ITC using a Bayesian framework. Results are given for all trials, Japanese trials, and international trials.

Results: Eight RCTs (duration 24-30 weeks) were included. Change in HbA1c with iGlarLixi was greater, and bodyweight trajectory was more favorable than with IDegAsp for all analyses (Figure). A greater percentage of people achieved HbA1c target (<7.0 % [<53 mmol/mol]) with iGlarLixi in all trials (odds ratio [95% credible interval] 2.50 [1.06, 5.56]) and Japanese trials (2.17 [1.27, 3.70]), but was not confirmed in international trials (2.17 [0.42, 11.11]). Exploratory analysis suggested favorable differences in change in pre-meal self-measured plasma glucose (SMPG; all trials and international trials) and post-meal SMPG (all analyses) with iGlarLixi vs. IDegAsp. Hypoglycemia comparisons were inconclusive due to different definitions.

Conclusion: iGlarLixi offers clinical benefit in glycemic control and weight change vs. IDegAsp in those requiring both basal plus meal-time insulin interventions.


P. Home: Consultant; Self; American Diabetes Association, Kriya Technologies, Sanofi, Other Relationship; Self; Association of British Clinical Diabetologists, AstraZeneca, Novartis Malaysia, Sanofi, Research Support; Self; Sanofi. R. Mehta: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Speaker’s Bureau; Self; Abbott, Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc. K. Hafidh: None. O. Gurova: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk, Sanofi, STADA, Takeda Pharmaceutical Co. A. Alvarez: Employee; Self; Sanofi. P. Serafini: Other Relationship; Self; Sanofi. M. Pourrahmat: Other Relationship; Self; Sanofi.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at